Aberrant expression of IL-23/IL-23R in patients with breast cancer and its clinical significance

Abstract

Breast cancer tissues and adjacent tissues were collected from 32 patients who were treated in The Third Hospital of Chengde City. Reverse transcription‑quantitative polymerase chain reaction results demonstrated that, compared with the adjacent tissues, interleukin (IL)‑23/IL‑23 receptor (R) gene expression levels were notably higher in breast cancer tissues. Furthermore, IL‑23 and IL‑23R expression levels were positively correlated with patients' tumor size, TNM stage and metastasis. Recombinant human (rh) IL‑23 (10 ng/ml) was used for the stimulation of the MCF‑7 cell line. Effects of rh IL‑23 (10 ng/ml) on cell proliferation was detected after MCF‑7 cells were incubated with rh IL‑23 for 48 h. Whether pre‑treatment with polyclonal antibody (PAb) IL‑23p19, a neutralizing antibody specific for IL‑23, may influence the effects of IL‑23 on cell behavior was also investigated. Cell proliferation assay and cell apoptosis assay were evaluated using MTT assay and flow cytometry assay, respectively. Results suggested that PAb IL‑23p19 reduced IL-23-induced cell proliferation whereas induced IL‑23 inhibited cell apoptosis. Western blot analysis was performed for the detection of molecules that may be responsible for the aforementioned changes. Results indicated that PAb IL‑23p19 treatment reduced IL‑23‑induced upregulation of B‑cell lymphoma‑2 protein expression and activation of the janus kinase 2/signal transducer and activator of transcription 3 signaling pathway. The present results suggested that IL‑23 may be a potential prognosis marker and target for the treatment of breast cancer patients.

Malassezia‐derived aryl hydrocarbon receptor ligands enhance the CCL20/Th17/soluble CD163 pathogenic axis in extra‐mammary Paget's disease

“…Another proinflammatory cytokine, IL‐23, also plays important roles in inducing Th17 cell proliferation and tumor development in breast cancer . In addition to inducing IL‐17 expression, IL‐23 inhibits apoptosis of MCF‐7 breast cancer cells, thus promoting tumor progression .…”

“…Another proinflammatory cytokine, IL‐23, also plays important roles in inducing Th17 cell proliferation and tumor development in breast cancer . In addition to inducing IL‐17 expression, IL‐23 inhibits apoptosis of MCF‐7 breast cancer cells, thus promoting tumor progression . Moreover, levels of IL‐23 and IL‐23R expression are positively correlated with tumor size, tumor‐node‐metastasis stage and metastasis in breast cancer, suggesting a significant role for IL‐23 in the pathogenesis of breast cancer.…”

IL-23 Expression in Stewart-Treves Syndrome: Two Case Reports and Immunohistochemical Investigation

“…Indeed, as we have previously reported, Paget's cells as well as dermal myeloid cells produce IL-23, leading to the induction of IL-17 in the lesional skin in extramammary Paget's cells [7]. In addition to inducing IL-17 expression, IL-23 inhibits apoptosis; thus, promoting tumor progression [6]. In aggregate, IL-23 could be a key trigger for the induction of IL-17, leading to IL-17-producing cells in skin cancers.…”

“…IL-23 plays an important role in inducing Th17 cell proliferation as well as in the angiogenesis of tumors [3][4][5][6][7]. Indeed, Nie et al [4] reported that IL-23 promotes the recruitment of M2 macrophages and neutrophils, which secrete immunosuppressive cytokines and vascular endothelial growth factor as well as matrix metalloproteinase 9 (MMP9) into tumor tissues.…”

Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab

“…Pro-inflammatory cytokines IL-23 and IL-17 could play crucial roles in tumor development in cutaneous SCC. 4,5 In addition to inducing IL-17, IL-23 inhibits tumor cell apoptosis, clinically affecting the tumor progression. IL-17 induces the proliferation of keratinocytes and tumorigenesis, including that of cutaneous SCC.…”